The SUCRA scores (dapagliflozin, 0.815; empagliflozin, 0.685; and placebo, 0.001) further emphasize the superiority of both SGLT2 inhibitors over placebo, with dapagliflozin slightly favored in this ranking for preventing hospitalizations for heart failure. The gene discussed is SLC5A2; the disease is heart failure.